Switching Among Multiple Infliximab Biosimilars Does Not Cause Immunogenicity, Study Finds - The Center for Biosimilars

Switching Among Multiple Infliximab Biosimilars Does Not Cause Immunogenicity, Study Finds  The Center for Biosimilars

A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity in patients with ...